2011 financial briefs for Alkermes, Allergan, Gilead and Vertex

Among the plethora of financial results being reported by US biotech and pharmaceutical companies were also figures from Alkermes (Nasdaq: ALKS), Allergan (NYSE: AGN), Gilead Sciences (Nasdaq: GILD) and Vertex Pharmaceuticals (Nasdaq: VRTX), which briefly are as follows:

Alkermes reported its first full quarter earnings (three months to December 31, 2011) for the combined company since its $960 million acquisition of Elan Drug Technologies which completed last fall (The Pharma Letter September 19, 2011). Revenue for the third quarter of the 2011/12 fiscal year was $126 million (versus consensus estimates of $114 million), with net loss at $0.11 per share (vs consensus of $0.22 per share). The company raised its revenue guidance for fiscal 2012 to $370-$400 million (previously $350-$380 million) and diluted adjusted EBITDA per share to $0.54-$0.63 (previously $0.38-$0.46) after US approval of its diabetes drug Bydureon (exenatide extended release; marketed by Amylin) which finally came through last month (TPL January 30).

Allergan’s revenue rose 7% in the fourth quarter to $1.4 billion and was in line with consensus estimates. Adjusted earnings per share for the quarter at $1.00 (up 14%, were also in line with consensus. The company issued guidance for full year 2012 EPS of $4.13-$4.19 and revenue of $5.65-$5.85 billion.